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externally validate clinical prediction models for outcomes after transsphenoidal surgery for acromegaly.
Methods Using data from two registries, we develop and externally validate machine learning models
for GTR, BR, and CSF leaks after endoscopic transsphenoidal surgery in acromegalic patients. For the
model development a registry from Bologna, Italy was used. External validation was then performed us-
ing data from Zurich, Switzerland. Gender, age, prior surgery, as well as Hardy and Knosp classification
were used as input features. Discrimination and calibration metrics were assessed. Results The derivation
cohort consisted of 307 patients (43.3% male; mean [SD] age, 47.2 [12.7] years). GTR was achieved in 226
(73.6%) and BR in 245 (79.8%) patients. In the external validation cohort with 46 patients, 31 (75.6%)
achieved GTR and 31 (77.5%) achieved BR. Area under the curve (AUC) at external validation was 0.75
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and Hardy grading contributed most to the predictions of BR and CSF leaks, respectively. Conclusions
Gross total resection, biochemical remission, and CSF leaks remain hard to predict, but machine learning
offers potential in helping to tailor surgical therapy. We demonstrate the feasibility of developing and
externally validating clinical prediction models for these outcomes after surgery for acromegaly and lay
the groundwork for development of a multicenter model with more robust generalization.
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Abstract
Purpose Biochemical remission (BR), gross total resection (GTR), and intraoperative cerebrospinal fluid (CSF) leaks are
important metrics in transsphenoidal surgery for acromegaly, and prediction of their likelihood using machine learning
would be clinically advantageous. We aim to develop and externally validate clinical prediction models for outcomes after
transsphenoidal surgery for acromegaly.
Methods Using data from two registries, we develop and externally validate machine learning models for GTR, BR, and CSF
leaks after endoscopic transsphenoidal surgery in acromegalic patients. For the model development a registry from Bologna, Italy
was used. External validation was then performed using data from Zurich, Switzerland. Gender, age, prior surgery, as well as
Hardy and Knosp classification were used as input features. Discrimination and calibration metrics were assessed.
Results The derivation cohort consisted of 307 patients (43.3% male; mean [SD] age, 47.2 [12.7] years). GTR was achieved in
226 (73.6%) and BR in 245 (79.8%) patients. In the external validation cohort with 46 patients, 31 (75.6%) achieved GTR and 31
(77.5%) achieved BR. Area under the curve (AUC) at external validation was 0.75 (95% confidence interval: 0.59–0.88) for GTR,
0.63 (0.40–0.82) for BR, as well as 0.77 (0.62–0.91) for intraoperative CSF leaks. While prior surgery was the most important
variable for prediction of GTR, age, and Hardy grading contributed most to the predictions of BR and CSF leaks, respectively.
Conclusions Gross total resection, biochemical remission, and CSF leaks remain hard to predict, but machine learning offers
potential in helping to tailor surgical therapy. We demonstrate the feasibility of developing and externally validating clinical
prediction models for these outcomes after surgery for acromegaly and lay the groundwork for development of a multicenter
model with more robust generalization.
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Introduction
Acromegaly is a rare, progressive disease, caused by an
oversecretion of growth hormone (GH) and elevated levels of
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insulin-like growth factor 1 (IGF-1) in the bloodstream [1]. A
GH-secreting pituitary tumor is the cause of acromegaly in
more than 95% of patients and surgical treatment remains the
first-line therapy in most cases [2].
There are many variables that play into the likelihood of
surgical success and endocrinological remission, such as
age, Knosp grade, repeat surgeries, or even different soma-
tostatin receptor subtypes [3–5]. The more factors that come
into play, the harder it gets for clinicians to take them and
their interactions into account. Based on these patient fea-
tures, machine learning (ML) can be implemented to tailor
treatment to a patient’s individual characteristics in the era of
“personalized medicine” [6]. It has become evident that ML
has strong potential for outcome prediction and sometimes
even outperforms statistical modeling techniques [7, 8].
The ability to predict the likelihood of outcomes such as
gross total resection (GTR) and biochemical remission (BR) as
well as complications that are clinically relevant such as
intraoperative cerebrospinal fluid (CSF) leaks from simple
information available pre-operatively would be beneficial in
risk-benefit patient counseling and shared decision-making.
For some complications such as intraoperative CSF leaks,
modifiable risk factors could even be adjusted based on per-
sonal risk, and precautions such as lumbar drainage could be
taken in individuals with a high predicted risk of CSF leaks
[9]. For this reason, we aim to develop and externally validate




A registry of patients who underwent endoscopic trans-
sphenoidal surgery from the Department of Neurosurgery,
IRCCS Institute of Neurological Sciences of Bologna was
used to train prediction models for GTR, BR, and intrao-
perative CSF leaks. External validation was then carried out
using patient data from the Department of Neurosurgery,
University Hospital Zurich. This study was conducted
conforming to the methods of transparent reporting of a
multivariable prediction model for individual prognosis or
diagnosis (TRIPOD) statement [10].
Data sources
Prospective databases from two centers were used for model
development. All patients who underwent surgery for acro-
megaly using the endoscopic transsphenoidal approach in
Bologna from August 1998 to January 2020, as well as from
July 2013 to May 2020 in Zurich were retrospectively eval-
uated. Operative procedures and preoperative assessments
were conducted as described in previous publications [11, 12].
The inclusion criterion was for one or more of the three out-
come measures (GTR, BR, and CSF leaks) to be available.
Exclusion criteria were transcranial or combined procedures.
Outcome measures
The ML models were developed to predict the subsequent
binary endpoints: GTR, BR, and intraoperative CSF leaks. The
primary outcome was GTR. The extent of resection was
measured in a 3-month postoperative volumetric MRI and
calculated as the percentage-wise reduction of tumor volume
compared to baseline tumor volume on preoperative MRI. An
extent of resection of 100% was defined as GTR. All mea-
surements were performed by a board-certified neurosurgeon
with extensive experience in pituitary surgery and imaging and
were continually entered into the prospective registry. BR was
strictly defined as normalization of hypersecretion into the
normal reference range as defined by accepted international
guidelines [13]. BR was defined as postoperative HGH level
random or after oral glucose tolerance test <0.4 μg/l with
normalization of age-adjusted IGF-1 levels at least 12 weeks
after surgery and no clinical signs of GH activity. Cases with
persistent slightly elevation of IGF-1 levels were considered in
remission if HGH level after OGTT was adequately sup-
pressed and no clinical signs of hormonal activity were pre-
sent. The HGH and IGF-1 were measured using the
chemiluminescence-Immunoassay LIAISON® hGH and
LIAISON® IGF-I, respectively. The analyses were performed
on the Liaison XL-Machine (DiaSorin, Saluggia, Italy).
Note that supplemental treatment modalities such as
medical and radiation therapy were also taken into account
when calculating BR.
Input variables
Furthermore, we collected the following baseline variables:
age, gender, prior surgery, Hardy classification (sellar and
suprasellar) [14], Knosp classification [15], and tumor size.
The Hardy and Knosp classifications both describe tumor
morphology and correlate with resectability: While the Hardy
classification focuses on intrasellar growth patterns and
suprasellar extension, the Knosp classification assesses risk of
cavernous sinus invasion by considering parasellar tumor
extension relative to the internal carotid arteries [14, 15]. We
defined macroadenoma as tumor size greater than 10mm [16].
Model development and validation
Continuous data are reported as mean value ± standard
deviation (SD), while categorical data are given as absolute
numbers (percentages). Models were trained on data from
Bologna, and subsequently externally validated in Zurich.
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Both data sets were randomly reordered and then checked for
approximately equal class distribution. There was no need for
recursive feature elimination as only a limited number of
variables were purposefully used.
A wide range of ML algorithms was applied including
traditional and Bayesian generalized linear models (GLM),
generalized additive models, random forests, stochastic
gradient boosting machines (GBM) and a shallow neural
network. They were tuned according to the area under the
receiver operating characteristics curve (AUC) in fivefold
repeated cross validation with ten iterations. A k-nearest
neighbor algorithm was trained in parallel, allowing impu-
tation of any missing data [17]. Binarization of predicted
probabilities was carried out using a threshold based on the
closest-to-(0,1)-criterion [18] on the derivation cohort.
Discrimination was assessed using AUC, accuracy, sensi-
tivity, specificity, positive predictive value (PPV), and
negative predictive value (NPV). We also assessed cali-
bration intercept and slope. Nonparametric 95% confidence
intervals (CI) of the discrimination and calibration metrics
were computed in 1000 bootstrap resamples. Variable
importance was assessed for each model using a universal
AUC-based method, and importance measures were scaled
from 0 to 100 for each model [19]. All evaluations were
executed using R version 4.0.2 [20].
Results
Patient cohort
In total, 307 patients were used in the training process. The
training data had no missing values apart from the age of a
single patient. Mean age was 47.2 ± 12.7 years and 133
(43.3%) patients were male. GTR and BR were achieved in
226 (73.6%) and 245 (79.8%) patients, respectively, and
CSF leaks occurred intraoperative in 38 (12.5%) of patients.
The external validation cohort consisted of 46 patients,
among whom there were 5 (10.9%) patients with incom-
plete data on GTR and 6 (13.0%) patients with incomplete
data on BR. Only four (8.7%) patients in the external
validation set had incomplete baseline data. Mean age was
47.5 ± 14.4 years and 22 (47.8%) patients were male. In the
external validation cohort, GTR occurred in 31 (75.6%)
patients, while BR occurred in 31 (77.5%). Intraoperative
CSF leaks occurred in 12 (26.1%) patients in the external
validation cohort. Detailed patient characteristics for both
cohorts are provided in Table 1.
Model performance
Gross total resection
A detailed overview of model performance is provided in
Table 2, including calibration metrics and training perfor-
mance. At external validation, the GTR model (traditional
GLM) achieved an AUC of 0.75 (0.59–0.88), 0.52
(0.33–0.70) for sensitivity and 0.90 (0.69–1.00) for speci-
ficity. The resulting PPV was 0.94 (0.82–1.00).
Biochemical remission
Our GBM achieved an AUC of 0.63 (0.40–0.82) on the
external validation data, as well as a sensitivity of 0.61
(0.44–0.77) and specificity of 0.44 (0.12–0.80). A PPV of
0.79 (0.61–0.95) was reached.






Male gender, n (%) 133 (43.3%) 22 (47.8%)
No. missing 0 (0.0%) 0 (0.0%)
Age [yrs.]
Mean ± SD 47.2 ± 12.7 47.5 ± 14.4
Median (IQR) 55 (38–57) 46 (37–60)
Range 13–78 21–73
No. missing 1 (0.3%) 0 (0.0%)
Prior surgery, n (%) 49 (16%) 10 (21.7%)
No. missing 0 (0.0%) 0 (0.0%)
Hardy sellar, n (%) 236 (76.9%) 42 (91.3%)
Grade 1 514 (21.1%) 14 (30.4%)
Grade 2 324 (13.3%) 10 (21.7%)
Grade 3 243 (10.0%) 3 (6.5%)
Grade 4 121 (5.0%) 15 (32.6%)
No. missing 0 (0.0%) 3 (6.5%)
Hardy suprasellar, n (%) 174 (56.7%) 21 (45.6%)
Grade A 109 (35.5%) 13 (28.3%)
Grade B 20 (6.5%) 6 (13.0%)
Grade C 2 (0.7%) 1 (2.2%)
Grade D 3 (1%) 0 (0%)
Grade E 40 (13%) 1 (2.2%)
No. missing 0 (0.0%) 1 (2.2%)
Knosp classification, n (%) 96 (31.3%) 31 (67.4%)
Grade 1 24 (7.8%) 7 (15.2%)
Grade 2 27 (8.8%) 6 (13.0%)
Grade 3 30 (9.8%) 15 (32.6%)
Grade 4 15 (4.9%) 3 (6.5%)
No. missing 0 (0.0%) 0 (0.0%)
Macroadenoma, n (%) 199 (64.8%) 36 (80.0%)
No. missing 0 (0.0%) 1 (2.2%)
Gross total resection (GTR), n (%) 226 (73.6%) 31 (75.6%)
No. missing 0 (0.0%) 5 (10.9%)
Intraop. CSF leak, n (%) 38 (12.5%) 12 (26.1%)
No. missing 0 (0.0%) 0 (0.0%)
Biochemical remission, n (%) 245 (79.8%) 31 (77.5%)
No. missing 0 (0.0%) 6 (13.0%)
SD standard deviation, IQR interquartile range
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Cerebrospinal fluid leaks
The Bayesian GLM used to predict CSF leaks displayed an
AUC of 0.77 (0.62–0.91) at external validation, while a
sensitivity of 0.58 (0.29–0.87) and a specificity of 0.74
(0.57–0.88) were recorded. The NPV reached 0.83
(0.69–0.96).
Variable importance
Table 3 provides an overview of variable importance
measures for each of the three models. For prediction of
GTR, prior surgery and Hardy grading contributed most to
predictions. Patient age and Hardy grading contributed most
to predictions of BR. Last, Hardy and Knosp grading con-
tributed most to predictions of intraoperative CSF leaks
(Fig. 1).
Discussion
In this study, the feasibility of predicting surgical and
endocrinological outcome after transsphenoidal surgical
treatment of acromegaly was evaluated. With data from two
registries, three clinical prediction models were trained and
subsequently externally validated. The achieved results
proved to be promising and thereby displayed that there is
significant potential for clinical application of ML.
In surgical treatment of acromegaly, normalization of
GH levels through total resection is crucial. Treatment-
refractory acromegaly puts patients at risk for early mor-
tality [21]. Consequently, a more aggressive surgical
approach is justified in refractory cases. It has been proven
that the percentage of reduction in GH closely correlates
with the fraction of removed tumor in surgery for acrome-
galy [22]. Further, low serum GH levels indicate persisting
remission, whereas with higher levels the probability of
recurrent disease—linked to significant mortality —is
markedly larger [23, 24]. Even intraoperative CSF leaks are
detrimental to endocrinological outcomes, since they have
Table 2 Discrimination and calibration metrics of the machine learning-based prediction models
Outcome Gross total resection Biochemical remission CSF leak














AUC 0.68 (0.66–0.70) 0.75 (0.59–0.88) 0.62 (0.59–0.64) 0.63 (0.40–0.82) 0.69 (0.67–0.72) 0.77 (0.62–0.91)
Accuracy 0.65 (0.63–0.67) 0.61 (0.46–0.75) 0.63 (0.61–0.64) 0.58 (0.42–0.72) 0.60 (0.58–0.62) 0.70 (0.57–0.83)
Sensitivity 0.65 (0.63–0.67) 0.52 (0.33–0.70) 0.64 (0.63–0.67) 0.61 (0.44–0.77) 0.71 (0.66–0.75) 0.58 (0.29–0.87)
Specificity 0.65 (0.61–0.68) 0.90 (0.69–1.00) 0.57 (0.53–0.61) 0.44 (0.12–0.80) 0.59 (0.57- 0.61) 0.74 (0.57- 0.88)
PPV 0.84 (0.82–0.85) 0.94 (0.82–1.00) 0.85 (0.84–0.87) 0.79 (0.61–0.95) 0.19 (0.17–0.22) 0.44 (0.20–0.69)
NPV 0.40 (0.37–0.43) 0.38 (0.18–0.57) 0.27 (0.26–0.31) 0.25 (0.06–0.47) 0.93 (0.92–0.95) 0.83 (0.69–0.96)
Calibration
Intercept 0.97 1.49 1.29 1.14 −1.77 −0.64
Slope 0.52 0.03 0.58 0.76 0.39 0.68
Threshold 0.55 0.52 0.41
Metrics are provided with bootstrapped 95% confidence intervals
AUC area under the curve, PPV positive predictive value, NPV negative predictive value







Male gender 58.24 0.00* 0.00*
Age 56.51 100.00 12.11
Prior surgery 100.00 2.71 14.37
Hardy sellar 47.47
Grade 1 0.02 9.36
Grade 2 25.16 1.93
Grade 3 51.03 0.00*
Grade 4 0.30 0.00*
Hardy suprasellar 100.00
Grade A 90.49 2.67
Grade B 93.01 13.21
Grade C 0.00* 0.00*
Grade D 0.12 0.00*
Grade E 72.18 14.77
Knosp classification 72.88
Grade 1 6.71 0.00*
Grade 2 63.30 4.81
Grade 3 25.54 0.00
Grade 4 8.19 15.14
Macroadenoma 21.24 7.48 67.41
*Corresponds to a variable importance of 0.00, i.e., the variable was
not included in the final model
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been shown to inhibit hormonal recovery after surgery—
apart from their inherent risk for persisting CSF fistulas and
meningitis [25, 26].
Surgical outcome depends on many variables that are
hard to account for—including surgical experience, skill,
and caseload [2]—making their prediction difficult. ML
methods can deduce a simple risk assessment model from
relatively complex data [4, 5]. For this reason, ML has been
proven to aid in improved shared decision-making as well
as enhanced patient care by modification of risk factors
[7, 27, 28]. However, some factors cannot be taken into
account by any model—prediction models will always
remain just that: models of reality. Therefore, ML should
never replace the careful study of imaging results, the
contemporary literature, and surgical experience. Rather, it
should be seen as supplemental information available to
surgeons, complementing the existing evidence and allow-
ing personalized risk-benefit assessment. There is decent
evidence that ML can help with improved surgical decision-
making, and in some cases may even outperform expert
predictions [28].
Other important parameters that help physicians include
simple scores and classifications, like the Knosp classifi-
cation [29] or the Zurich Pituitary Score [30]. While these
scores are well validated and robustly predict e.g. GTR,
they are rather difficult to tailor to specific patient char-
acteristics because they stratify patients into large risk
groups. For the ML models established in this investigation,
some of these classifications were combined with other
recognized prognostic factors to deliver predictions that are
precisely tailored to each patient. When trying to compare
the performance of ML models with these scoring systems,
little valid comparisons can be made, since reporting of
performance measures such as sensitivity and specificity for
these scores is uncommon. A systematic review by Dhan-
dapani et al. [31] allows comparison to the raw Knosp
classification and its relationship with GTR. This review
found that the usual dichotomization of the Knosp classi-
fication (Knosp 1 and 2 vs. Knosp 3 and 4) led to a sen-
sitivity of 66.4% and specificity of 90.3% for GTR [31].
Furthermore, in future studies, by combining additional
endocrinological parameters like preoperative IGF-1 or
early postoperative GH value in the model, a better per-
formance for BR prediction might be obtained [32–34].
However, the rationale of this study was to develop a simple
tool that can give meaningful predictions using basic, pre-
operatively available data only.
The developed models demonstrated good general-
izability, performing similarly well on the external valida-
tion data as compared to on the training data. The GTR and
BR models had a high PPV, making them suitable as “rule-
in” models. Conversely, the CSF leak model demonstrated a
high NPV, and is thus more suitable in a “rule-out” setting.
A major criticism of ML-based prediction models is that
they at times work like a “black box” [35]. Especially with
deep neural networks, one is often confronted with the
inability to understand why certain predictions have been
made. By feeding the algorithm with the required data it can
often provide precise outcome prediction, but it remains
unknown how the internal decision-making process works.
In this study, an initial problem was solved firstly by relying
on algorithms with a complexity suitable to tabulated
medical data. In addition, insight into the decision-making
procedure can be gained by evaluating the variable
Fig. 1 AUC-based variable importance for the three models. Importance values have been scaled from 0 to 100. A Gross total resection;
B Biochemical remission; C Intraoperative cerebrospinal fluid leakage
Endocrine
importance listed in Table 3. With ML, interpretability can
involve an inherent trade-off for better prediction power.
In conclusion, it can be stated that prediction of these
complex outcomes like BR and GTR–which are certainly
governed also by “unmeasurable” factors such as surgeon
experience—from simple input data remains a difficult task,
although ML can provide relatively accurate predictions in
this pilot study already. Using more complex variables as
input instead would probably improve the performance, but
too complex inputs could be undesirable, as they would
make the application of the models impractical. This study
aimed at creating a simple tool that can give meaningful
predictions using basic, pre-operatively available data. The
models developed are proof that this is no longer mere
wishful thinking. To the best of the authors’ knowledge,
there are no other published, externally validated clinical
prediction models for outcomes of transsphenoidal pituitary
surgery in acromegalic patients. Once these models are
enhanced by additional patient data and more participating
centers to foster generalizability, an integration into a web
application available to the public would be feasible.
Limitations
The main limitation of our study is the relatively low sample
size. Although a very decent surgical cohort of over 300
acromegalic patients was included for training— one of the
largest contemporary single-center cohorts in the literature—
this sample size is still rather low for ML. For example,
evaluation of model calibration usually requires larger
amounts of data. Recalibration would not change anything in
this respect, and would only artificially improve calibration
[36, 37]. Larger amounts of data would also likely improve
general model performance. Even though external validation
was carried out, which demonstrated generalizability of our
models, including more participating centers to create a
multicenter model that may account for the differences in
surgical strategies, and so forth. Another important factor to
consider is that these models are not applicable to centers
with radically different treatment protocols. Importantly,
surgical outcomes are also influenced by surgical experience
and caseload [38], inherently limiting the generalizability of
any prediction model, score, or classification for surgical
outcome. For example, a significantly different endpoint
incidence may lead to systematic over- or underestimation of
the outcome probability from the developed models [36].
Furthermore, it needs to be taken into account that all clinical
prediction models are unable to reliably predict extreme cases
that fall outside the range of the training data (extrapolation)
[39, 40]. Furthermore, our models are trained on “real-world”
registry data. The rate of BR was higher than the rate of GTR
due to supplemental treatments such as radiation and medical
therapy. While this does represent the “real-world” clinical
practice—with some patients undergoing multiple treatments
—our models may be less suitable when aiming to predict
the chances of BR purely from tumor resection. Problems
may also occur because of the poor reliability between dif-
ferent physicians’ ratings [41, 42]. Especially with the Knosp
and Hardy classification, there is evidence for poor inter-rater
reliability.
Conclusions
GTR, BR, and CSF leaks remain hard to predict, but ML
may offer remarkable potential in helping to tailor surgical
therapy. We demonstrate the feasibility of developing and
externally validating clinical prediction models for these
outcomes after surgery for acromegaly. This study lays the
groundwork for development of a multicenter model with
more robust generalization.
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